18F-FTC-146 PET/CT in Newly-Diagnosed Osteosarcoma

Phase 2

Terminated

• Conditions: Osteosarcoma
• Interventions: Drug: 18-F FTC 146

• Registration Number: NCT04365660
• Lead Sponsor: Davidzon, Guido, M.D.

Brief Summary

The purpose of this research is to evaluate the study drug, 18F FTC-146, as a positron emission tomography (PET) / computed tomography (CT) radiotracer imaging agent to evaluate tumor status in patients newly diagnosed with osteosarcoma ("bone cancer").

Detailed Description

Primary Objective: Demonstrate correlation of pre-post reduction in 18F-FTC-146 PET/CT with amount of post-treatment tumor necrosis in newly-diagnosed and treated osteosarcoma patients.

Secondary Objective: Demonstrate correlation of pre-post reduction in 18F-FTC-146 PET/CT with amount of post-treatment pain reduction in newly-diagnosed and treated osteosarcoma patients.

Study Timeline

• Study First Submitted: 2020-04-24
• Study First Submitted QC: 2020-04-24
• Study First Posted: 2020-04-28
• Study Start: 2021-01-28
• Primary Completion: 2021-05-28
• Study Completion: 2021-07-22
• Results First Submitted: 2023-09-28
• Status Verified: 2023-10
• Results First Submitted QC: 2023-10-26
• Last Update Submitted: 2023-10-26
• Results First Posted: 2023-11-14
• Last Update Posted: 2023-11-14

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 1

Inclusion Criteria

• Patients with biopsy proven osteosarcoma requiring local surgical intervention.
• ECOG ≤ 2
• Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria

• Chemotherapy in the past 2 months.
• Prior history of allergic reaction to 18F FTC 146.
• Pregnant or nursing

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
18-F-FTC 146 PET/CT	18-F FTC 146	For PET scans, subjects will receive intravenous injection of 10 mCi 18-F -FTC 146 administered twice with 18-F-FTC 146, once at baseline (pre chemotherapy) and once at final study visit (post chemotherapy).

Primary Outcome Measures

Name	Time	Method
Detection of Tumor Necrosis Post-chemotherapy	12 weeks	Participants will be assessed with 18F FTC 146 PET/CT imaging at baseline and after neoadjuvant (pre surgery) chemotherapy but before surgery itself. Chemotherapy will be nominally three 3 week cycles administered over up to 12 weeks. The ability of 18F FTC 146 PET/CT to evaluate treatment effect will be assessed as the percentage of tumor that is assessed as necrotic after the treatment course. The outcome will be reported as the mean percentage of the resected tumor (removed by surgery) that is assessed by histopathology as necrotic, with standard deviation.

Secondary Outcome Measures

Name	Time	Method
Maximum Standardized Uptake Value (SUVmax)	12 weeks	Participants will be assessed with 18F FTC 146 PET/CT imaging at baseline and after neoadjuvant (pre surgery) chemotherapy but before surgery itself. Chemotherapy will be nominally three 3 week cycles administered over up to 12 weeks. Based on the PET/CT scans, the maximum standardized uptake value (SUVmax) in the tumor region of interest (ROI) will be calculated at baseline and after treatment. The outcome will be reported as the mean percent change in SUVmax from baseline to post treatment, with standard deviation.
Use of Patient Reported Outcomes Measurement Information System (PROMIS) to Assess Treatment Effect	12 weeks	Participants will receive neoadjuvant (pre surgery) chemotherapy, nominally three 3 week cycles administered over up to 12 weeks. The treatment effect of the neoadjuvant chemotherapy will be assessed as the change in scores on the PROMIS (Patient Reported Outcomes Measurement Information System) questionnaire, from baseline to post treatment. The result will be reported as the mean difference from baseline to post treatment, with standard deviation.

Trial Locations

Locations (1)

Stanford University; 🇺🇸 Stanford, California, United States